

new claims 46-57 may be found generally throughout the specification and the claims as originally filed. For instance, exemplary support for claims 46-50 and 53 may be found at page 11, lines 25-31 as well as in claim 35 as originally filed. Support for claims 51 and 52 may be found, for example, in claims 35 and 36 as originally filed. Support for claims 54 and 55 may be found, for example at page 19, lines 22-27. Support for claims 56 and 57 may be found, for example, at page 11, lines 25-36.

Therefore, no new matter has been added.

In amending or canceling claims, Applicants reserve the right to pursue claims of equivalent or different scope in this and later applications. No claim amendment or cancellation should be viewed as an acquiescence to a rejection.

MARK-UP OF CLAIM AMENDMENTS USING STANDARD BRACKETS AND UNDERLINES:

The claim amendments are shown with respect to the claims as pending after the Examiner's amendment and Notice of Allowance.

34. **(As Allowed)** An isolated nucleic acid comprising the nucleotide sequence as shown in SEQ ID.No. 2.

35. **(Canceled)**

45. **(Canceled)**

46. **(New)** An isolated nucleic acid which comprises between about 10 and 7000 consecutive nucleotides of SEQ ID NO:2, wherein said nucleic acid contains position 8845 of SEQ ID NO:2.

47. **(New)** An isolated nucleic acid of claim 46, which comprises between about 15 and 7000 consecutive nucleotides of SEQ ID NO:2.

48. **(New)** An isolated nucleic acid of claim 46, which comprises between about 20 and 7000 consecutive nucleotides of SEQ ID NO:2.

49. **(New)** An isolated nucleic acid of claim 46, which comprises between about 25 and 7000 consecutive nucleotides of SEQ ID NO:2.

50. **(New)** An isolated nucleic acid of claim 46, which comprises between about 30 and 7000 consecutive nucleotides of SEQ ID NO:2.

51. **(New)** An isolated nucleic acid of claim 46, which comprises between about 100 and 7000 consecutive nucleotides of SEQ ID NO:2.

52. **(New)** An isolated nucleic acid of claim 46, which comprises between about 5000 and 7000 consecutive nucleotides of SEQ ID NO:2.

53. **(New)** An isolated nucleic acid that is a complement of the isolated nucleic acid of claim 46.

54. **(New)** An isolated nucleic acid of claim 46, further comprising a label.

55. **(New)** The isolated nucleic acid of claim 54, wherein the label is selected from the group consisting of: a radiolabel, an enzyme, a fluorescent compound, streptavidin, avidin, biotin, a magnetic moiety, a metal-binding moiety, an antigen moiety and an antibody moiety.

56. **(New)** The nucleic acid of claim 46, wherein the nucleic acid is bound to a solid phase support.

57. **(New)** The nucleic acid of claim 46, wherein the nucleic acid is part of a probe array.

CONCLUSION


Applicants respectfully request continued examination of the pending application and the newly submitted claims. Applicants believe that the claims are in condition for allowance and early notification to this effect is earnestly solicited. If the Examiner believes that an interview would expedite the prosecution of this application, the Applicants would ask that the Examiner please contact their representative identified below at the Examiner's convenience.

If there are any other fees due in connection with the filing of this Response, please charge the fees to our Deposit Account No. 06-1448. If a fee is required for an extension of time under 37 C.F.R. §1.136 not accounted for above, such an extension is requested and the fee should also be charged to our Deposit Account.

Respectfully submitted,

FOLEY, HOAG & ELIOT

Dated: January 3, 2001



John D. Quisel
Reg. No. 47,874
Agent for Applicants

Patent Group
Foley, Hoag & Eliot, LLP
One Post Office Square
Boston, MA 02109-2170
Tel.: (617) 832-1000
Fax: (617) 832-7000